Rustum Y - Search Results

1

Potential regional differences for the tolerability profiles of fluoropyrimidines.

Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O'Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzén F, Twelves C. Haller DG, et al. Among authors: rustum y. J Clin Oncol. 2008 May 1;26(13):2118-23. doi: 10.1200/JCO.2007.15.2090. J Clin Oncol. 2008. PMID: 18445840

2

Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.

Köhne-Wömpner CH, Schmoll HJ, Harstrick A, Rustum YM. Köhne-Wömpner CH, et al. Among authors: rustum ym. Semin Oncol. 1992 Apr;19(2 Suppl 3):105-25. Semin Oncol. 1992. PMID: 1373004 Review.

3

Enhancement of the antitumor effects of 5-fluorouracil by folinic acid.

Mini E, Trave F, Rustum YM, Bertino JR. Mini E, et al. Among authors: rustum ym. Pharmacol Ther. 1990;47(1):1-19. doi: 10.1016/0163-7258(90)90042-z. Pharmacol Ther. 1990. PMID: 2195551 Review.

4

Irinotecan in the treatment of colorectal cancer: clinical overview.

Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Vanhoefer U, et al. Among authors: rustum ym. J Clin Oncol. 2001 Mar 1;19(5):1501-18. doi: 10.1200/JCO.2001.19.5.1501. J Clin Oncol. 2001. PMID: 11230497 Review.

5

Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer.

Vanhoefer U, Harstrick A, Köhne CH, Achterrath W, Rustum YM, Seeber S, Wilke H. Vanhoefer U, et al. Among authors: rustum ym. J Clin Oncol. 1999 Mar;17(3):907-13. doi: 10.1200/JCO.1999.17.3.907. J Clin Oncol. 1999. PMID: 10071283 Clinical Trial.

6

Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors.

Rustum YM, Harstrick A, Cao S, Vanhoefer U, Yin MB, Wilke H, Seeber S. Rustum YM, et al. J Clin Oncol. 1997 Jan;15(1):389-400. doi: 10.1200/JCO.1997.15.1.389. J Clin Oncol. 1997. PMID: 8996166 Review.

7

The emerging role for biomodulation of antineoplastic agents.

Schmoll HJ, Hiddemann W, Rustum Y, Köhne-Wömpner CH. Schmoll HJ, et al. Among authors: rustum y. Semin Oncol. 1992 Apr;19(2 Suppl 3):1-3. Semin Oncol. 1992. PMID: 1557636 No abstract available.

8

Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.

Harstrick A, Gonzales A, Schleucher N, Vanhoefer U, Lu K, Formento JL, Milano G, Wilke H, Seeber S, Rustum Y. Harstrick A, et al. Among authors: rustum y. Anticancer Drugs. 1998 Aug;9(7):625-34. doi: 10.1097/00001813-199808000-00008. Anticancer Drugs. 1998. PMID: 9773807

9

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.

Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. Fakih MG, et al. Clin Cancer Res. 2009 May 1;15(9):3189-95. doi: 10.1158/1078-0432.CCR-08-2999. Epub 2009 Apr 21. Clin Cancer Res. 2009. PMID: 19383814 Free PMC article. Clinical Trial.

10

Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study.

Tewes M, Schleucher N, Achterrath W, Wilke HJ, Frings S, Seeber S, Harstrick A, Rustum YM, Vanhoefer U. Tewes M, et al. Among authors: rustum ym. Ann Oncol. 2003 Sep;14(9):1442-8. doi: 10.1093/annonc/mdg376. Ann Oncol. 2003. PMID: 12954586 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

313 results

Search Page